Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters Market Overview:
Global PTCA Balloon Catheters Market was valued at $1,064 million in 2016, and is expected to reach $1,431 million by 2023, growing at a CAGR of 4.3% from 2017 to 2023. Percutaneous transluminal coronary angioplasty (PTCA) is a minimally-invasive procedure used to open blocked or narrowed coronary arteries. Use of PTCA balloons provides an effective minimally invasive approach to widen a narrowed coronary artery. During the procedure, an empty balloon (balloon catheter) is passed into narrow arteries with the help of a wire (generally a catheter). Once the balloon reaches the desired position, it is inflated. This results into the displacement of stenosis (narrowing) from the vessel wall. The balloon is removed after the procedure. PTCA is generally followed by stent placement, but is not mandatory.
Increase in ageing population and changes in lifestyle leading to hypertension, obesity, and other risk factors that lead to vascular disorders is expected to propel the growth of the PTCA balloon catheters market. In addition, technological advancements and reclassification of some PTCA catheters from class III to class II device by FDA, and increase in prevalence of cardiovascular disorders are expected to further drive the market growth. However, availability of alternative therapies, and complications associated with PTCA balloon catheters restrain this growth. The upsurge in demand for minimally invasive surgeries, rise in disposable incomes, and growth prospects in emerging economies of Asia-Pacific and LAMEA are expected to provide numerous opportunities for market growth during the forecast period.
PTCA Balloon Catheters Market Segmentation
The development of drug eluting balloons (DEBs) has increased the interest of several healthcare providers in the recent years as they provide localized drug delivery to the area of interest. Drug eluting balloons function in the same way as normal balloons but they provide an additional coating of anti-proliferative medicine, which prohibits cell division even after the removal of balloon catheter. DEBs were developed to overcome the limitations of drug eluting stents, which leads to restenosis. Hence, a DEB delivers drug, retains anti-proliferative properties of drug eluting stents, and eliminates the chances of restenosis. In addition, DEB can be used in subsets of lesions where drug eluting stents either do not perform well or cannot be delivered. Therefore, DEBs offer an efficient treatment option for the management of torturous vessels and small vessels, where a stent cannot be implanted, and bifurcated lesions and long diffused calcified lesions that may lead to stent fracture. Hence, there is an increase in demand for drug eluting balloons in the market. In addition, the development of technologically advanced products, such as the chocolate PTCA balloon catheter also boost the market growth.
PTCA Balloon Catheters Market, by Product, 2016 (%)
Snapshot of LAMEA PTCA Balloon Catheters Market
Increase in focus of the key players in LAMEA is primarily set to contribute to the growth of the market. The healthcare expenditure per capita is growing steadily in the region, which is expected to boost the growth. Increase in incidence of cardiovascular disorders coupled with the rapid growth of the geriatric patient population fuels the market. Moreover, the increase in number of technological advancements along with the focus and investments by major players is expected to provide several opportunities for market growth in the future. In addition, with the growing economies of these countries, people can now afford the cost of a complete procedure. This trend is expected to increase even more in the near future. Hence, a rapid growth of the PTCA balloon catheters market is expected during the forecast period in LAMEA.
Saudi Arabia PTCA Balloon Catheters Market, 2016-2023 ($Million)
The list of key players profiled in this report include Abbott Laboratories, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, C. R. Bard, Inc., Cardinal Health, Inc., Medtronic plc, MicroPort Scientific Corporation, Terumo Corporation, and THE SPECTRANETICS CORPORATION.
Key players in the value chain include Lepu Medical Technology (Beijing) Co., Ltd., Meril Life Sciences Pvt. Ltd., and COOK MEDICAL INC.
- The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2016 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Product and material segmentation analysis helps understand the various types of devices and materials used to manufacture PTCA balloons.
- Comprehensive analysis of all regions determines the prevailing opportunities.
- Key players are profiled and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the global market.
Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheters Market Key Segments:
- Normal balloon catheter
- Drug eluting balloon catheter
- Cutting balloon catheter
- Scoring balloon catheter
By Delivery Platform
- Rapid Exchange (RX) / Monorail balloon catheter
- Over-the-wire (OTW) balloon catheter
By Balloon Material
- Polyolefin copolymer (POC)
- Polyethylene (PE)
- Polyethylene terephthalate (PET)
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South Africa
- Saudi Arabia
- Rest of LAMEA